These results demonstrated that the combination of GOx and GalNAc‐modified LYTACs could significantly inhibit tumor growth in vivo and in vitro by relieving the immunosuppression generated by CD24/Siglec‐10 signal pathway. Here, SIGLEC10 is linked to neoplasm.